ALLOGENEIC MARROW TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME COMPLICATING AUTOLOGOUS BONE-MARROW TRANSPLANTATION

被引:1
作者
BASHIR, S
COOK, P
KATZ, M
MITTELMAN, A
AHMED, T
机构
[1] NEW YORK MED COLL,DEPT MED,VALHALLA,NY 10595
[2] YALE NEW HAVEN MED CTR,DEPT MED,NEW HAVEN,CT
关键词
D O I
10.3109/07357909409021407
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A patient with refractory relapsed Hodgkin's disease underwent an autologous bone marrow transplant in July 1987 and achieved remission of Hodgkin's disease. He had complete hematological recovery but developed pancytopenia 3 years post bone marrow transplantation with morphological evidence of myelodysplasia. High-dose cyclophosphamide, 200 mg/kg, chemotherapy followed by an allogeneic bone marrow transplant from a HLA-matched sibling was performed in April 1991 with complete hematological recovery. Allogeneic bone marrow transplantation was thus used successfully to treat a potential complication of autologous bone marrow transplantation.
引用
收藏
页码:484 / 487
页数:4
相关论文
共 40 条
  • [1] AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE CURRENT TECHNIQUES AND PROSPECTS
    AHMED, T
    [J]. CANCER INVESTIGATION, 1990, 8 (01) : 99 - 106
  • [2] AHMED T, 1989, LEUKEMIA, V3, P19
  • [3] ALLOGENEIC MARROW TRANSPLANTATION IN THE TREATMENT OF PRELEUKEMIA
    APPELBAUM, FR
    STORB, R
    RAMBERG, RE
    SHULMAN, HM
    BUCKNER, CD
    CLIFT, RA
    DEEG, HJ
    FEFER, A
    SANDERS, J
    STEWART, P
    SULLIVAN, K
    WITHERSPOON, R
    THOMAS, ED
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) : 689 - 693
  • [4] BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASIA - PRETREATMENT VARIABLES AND OUTCOME
    APPELBAUM, FR
    BARRALL, J
    STORB, R
    FISHER, LD
    SCHOCH, G
    RAMBERG, RE
    SHULMAN, H
    ANASETTI, C
    BEARMAN, SI
    BEATTY, P
    BENSINGER, WI
    BUCKNER, CD
    CLIFT, RA
    HANSEN, JA
    MARTIN, P
    PETERSEN, FB
    SANDERS, JE
    SINGER, J
    STEWART, P
    SULLIVAN, KM
    WITHERSPOON, RP
    THOMAS, ED
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (08) : 590 - 597
  • [5] APPELBAUM FR, 1987, BLOOD, V69, P92
  • [6] BACCARANI M, 1980, CANCER, V46, P1735, DOI 10.1002/1097-0142(19801015)46:8<1735::AID-CNCR2820460806>3.0.CO
  • [7] 2-3
  • [8] BCVPP CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE - EVIDENCE FOR GREATER DURATION OF COMPLETE REMISSION, GREATER SURVIVAL, AND LESS TOXICITY THAN WITH A MOPP REGIMEN
    BAKEMEIER, RF
    ANDERSON, JR
    COSTELLO, W
    ROSNER, G
    HORTON, J
    GLICK, JH
    HINES, JD
    BERARD, CW
    DEVITA, VT
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) : 447 - 456
  • [9] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS
    BONADONNA, G
    VALAGUSSA, P
    SANTORO, A
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) : 739 - 746
  • [10] PARTIALLY MATCHED BONE-MARROW TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    BUNIN, NJ
    CASPER, JT
    CHITAMBAR, C
    HUNTER, J
    TRUITT, R
    MENITOVE, J
    CAMITTA, BM
    ASH, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) : 1851 - 1855